Risk factors and construction of a risk prediction model for readmission due to hyperbilirubinemia in neonates with ABO hemolytic disease of the newborn.
10.7499/j.issn.1008-8830.2412037
- Author:
Pei-Xian YUE
1
;
Hong-Ling CAO
1
;
Rong LI
1
Author Information
1. Department of Neonatology, Chuxiong Yi Autonomous Prefecture People's Hospital, Chuxiong, Yunnan 675000, China.
- Publication Type:Journal Article
- Keywords:
ABO hemolytic disease;
Hyperbilirubinemia;
Neonate;
Readmission;
Risk factor
- MeSH:
Humans;
Infant, Newborn;
ABO Blood-Group System;
Risk Factors;
Patient Readmission;
Male;
Female;
Logistic Models;
Hyperbilirubinemia, Neonatal/therapy*;
Erythroblastosis, Fetal;
Bilirubin/blood*
- From:
Chinese Journal of Contemporary Pediatrics
2025;27(7):834-841
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To investigate the readmission rate and risk factors for readmission due to hyperbilirubinemia in neonates with ABO hemolytic disease of the newborn (ABO-HDN), and to construct a risk prediction model for readmission.
METHODS:Neonates diagnosed with hyperbilirubinemia due to ABO-HDN and hospitalized in the neonatal department between January 2021 and December 2023 were enrolled. Based on readmission status, neonates were divided into a readmission group and a control group. Clinical characteristics related to hyperbilirubinemia and risk factors for readmission were analyzed. Subsequently, a prediction model for readmission was constructed, and its predictive performance was evaluated.
RESULTS:A total of 483 neonates with hyperbilirubinemia due to ABO-HDN were included. The readmission rate was 13.0% (63 cases). Multivariate logistic regression analysis revealed that earlier age at phototherapy initiation, longer duration of phototherapy, occurrence of rebound hyperbilirubinemia, and higher levels of serum total bilirubin and indirect bilirubin at discharge were independent risk factors for hyperbilirubinemia readmission in ABO-HDN neonates (OR=2.373, 4.840, 6.475, 5.033, 1.336 respectively; P<0.05). A risk prediction model for ABO-HDN hyperbilirubinemia readmission was constructed based on these 5 risk factors. Model evaluation demonstrated good predictive performance.
CONCLUSIONS:Age at phototherapy initiation, duration of phototherapy, occurrence of rebound hyperbilirubinemia, and serum total bilirubin and indirect bilirubin levels at discharge are significant influencing factors for readmission due to hyperbilirubinemia in neonates with ABO-HDN. Close monitoring during discharge planning and follow-up management for such neonates is crucial to reduce readmission rates.
